Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
=========================================================================================================================================

* Vaia Florou
* Andrew E. Rosenberg
* Eric Wieder
* Krishna V. Komanduri
* Despina Kolonias
* Mohamed Uduman
* John C. Castle
* Jennifer S. Buell
* Jonathan C. Trent
* Breelyn A. Wilky

## Abstract

Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”.

The original article can be found online at 10.1186/s40425-019-0689-7

**Correction to: J ImmunoTher Cancer** 

**https://doi.org/10.1186/s40425-019-0689-7** 

Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells.”

should be replaced with

“Ipilimumab and AGEN1884 are IgG1 class antibodies. AGEN1884 data show CTLA-4 inhibition and activity against T regulatory cells (reference 8).”

*   © The Author(s).

**Open Access**This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated.

## Reference

1.  1. Florou , et al . Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J ImmunoTher Cancer. 2019;7:213 [doi:10.1186/s40425-019-0689-7](http://dx.doi.org/10.1186/s40425-019-0689-7) pmcid:6686562 
    
    [Abstract/FREE Full Text](http://jitc.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiaml0YyI7czo1OiJyZXNpZCI7czo3OiI3LzEvMjEzIjtzOjQ6ImF0b20iO3M6MTg6Ii9qaXRjLzcvMS8yODUuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)